Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associate...
Saved in:
Main Authors: | Claire MacNabb, D. Patton, J. S. Hayes |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Osteoporosis |
Online Access: | http://dx.doi.org/10.1155/2016/6217286 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of TNF-α-Induced Sclerostin on Osteocytes during Orthodontic Tooth Movement
by: Fumitoshi Ohori, et al.
Published: (2019-01-01) -
Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes
by: Theerawut Klangjareonchai, et al.
Published: (2014-01-01) -
The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions
by: Xuegang Li, et al.
Published: (2025-01-01) -
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
by: Alicia K. Morgans, et al.
Published: (2011-01-01) -
Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study
by: Fabio Massimo Perrotta, et al.
Published: (2018-01-01)